Key Takeaways
- • Janus Henderson Investors (NYSE/ASX: JHG) announced that its Biotech team won the HFM (Hedge Fund Manager) U.S. Performance Award for Sector Specialist for 2023, presented by With Intelligence.
- • The Sector Specialist category had 6 shortlisted funds, and judges weighed absolute performance, standard deviation of returns, and outperformance against the relevant HFM benchmark.
- • Portfolio Manager Andy Acker said biotech is "entering a golden age of innovation," citing attractive valuations and new growth initiatives.
- • Janus Henderson had approximately US$308 billion in assets under management as of September 30, 2023.
Summary
Janus Henderson Investors announced on November 13, 2023 that its Biotech team was recognized by With Intelligence with the HFM U.S. Performance Award for Sector Specialist for 2023, according to a Business Wire press release issued from Denver. The award recognizes the highest-achieving hedge funds, CTAs, and funds of hedge funds in the United States, and the Janus Henderson team won in the Sector Specialist category over other sector-specific teams.
The awards are open to US hedge fund, fund of funds and CTA firms. To be eligible, entrants must submit a three-year track record of monthly performance data through June 2023. Judges focus on absolute performance, standard deviation of returns and outperformance of the relevant HFM benchmark, and also consider relative AUM, strategy nature, track records and supporting materials.
Andy Acker, Portfolio Manager at Janus Henderson, said biotech "is entering a golden age of innovation" as advanced technologies drive rapid medical breakthroughs, and that the team sees "exceptional potential" in the sector given attractive valuations and new growth initiatives. Chief Executive Officer Ali Dibadj described the award as a testament to the team's track record, investing experience and ability to add value through active management and stock selection.
The biotech team uses deep fundamental research to identify companies trading at significant disparities from intrinsic value. Janus Henderson Group, headquartered in London and listed on the NYSE and ASX, reported approximately US$308 billion in assets under management and more than 2,000 employees as of September 30, 2023.
The awards are open to US hedge fund, fund of funds and CTA firms. To be eligible, entrants must submit a three-year track record of monthly performance data through June 2023. Judges focus on absolute performance, standard deviation of returns and outperformance of the relevant HFM benchmark, and also consider relative AUM, strategy nature, track records and supporting materials.
Andy Acker, Portfolio Manager at Janus Henderson, said biotech "is entering a golden age of innovation" as advanced technologies drive rapid medical breakthroughs, and that the team sees "exceptional potential" in the sector given attractive valuations and new growth initiatives. Chief Executive Officer Ali Dibadj described the award as a testament to the team's track record, investing experience and ability to add value through active management and stock selection.
The biotech team uses deep fundamental research to identify companies trading at significant disparities from intrinsic value. Janus Henderson Group, headquartered in London and listed on the NYSE and ASX, reported approximately US$308 billion in assets under management and more than 2,000 employees as of September 30, 2023.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.